Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer
NCT04968002Phase 3Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Major Pathological Response Rate. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04968002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968002.